There has been demonstrated to be a higher expression of IL-17 in the intestinal mucosa of patients with CD and UC (9), but it has been found that anti-IL-17 agents fail to show clinical efficacy and may cause exacerbations of symptoms (10–12) and clinical relapses in patients with IBD (13, 14). This evidence concerns the gene IL17A and inflammatory bowel disease.